ALPS Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $2.62M | Buy |
88,253
+22,730
| +35% | +$651K | 0.01% | 450 |
|
|
2026
Q2 | $1.96M | Buy |
65,523
+11,862
| +22% | +$337K | 0.01% | 529 |
|
|
2026
Q1 | $1.61M | Sell |
53,661
-130
| -0.2% | -$4.3K | 0.01% | 448 |
|
|
2025
Q4 | $1.76M | Buy |
53,791
+21,886
| +69% | +$707K | 0.01% | 416 |
|
|
2025
Q3 | $1.11M | Sell |
31,905
-3,473
| -10% | -$111K | 0.01% | 497 |
|
|
2025
Q2 | $990K | Sell |
35,378
-12,908
| -27% | -$346K | 0.01% | 501 |
|
|
2025
Q1 | $1.21M | Sell |
48,286
-5,169
| -10% | -$131K | 0.01% | 432 |
|
|
2024
Q4 | $1.47M | Buy |
53,455
+3,557
| +7% | +$99.2K | 0.01% | 394 |
|
|
2024
Q3 | $1.44M | Sell |
49,898
-1,553
| -3% | -$42.3K | 0.01% | 413 |
|
|
2024
Q2 | $1.27M | Buy |
51,451
+4,739
| +10% | +$134K | 0.01% | 413 |
|
|
2024
Q1 | $1.5M | Buy |
46,712
+990
| +2% | +$36.8K | 0.01% | 399 |
|
|
2023
Q4 | $1.86M | Sell |
45,722
-2,590
| -5% | -$95.3K | 0.01% | 342 |
|
|
2023
Q3 | $1.67M | Buy |
48,312
+191
| +0.4% | +$7.44K | 0.01% | 350 |
|
|
2023
Q2 | $1.96M | Buy |
48,121
+5,066
| +12% | +$207K | 0.02% | 311 |
|
|
2023
Q1 | $1.66M | Sell |
43,055
-1,581
| -4% | -$65K | 0.01% | 325 |
|
|
2022
Q4 | $1.98M | Buy |
44,636
+8,433
| +23% | +$355K | 0.02% | 299 |
|
|
2022
Q3 | $1.54M | Sell |
36,203
-2,961
| -8% | -$152K | 0.01% | 358 |
|
|
2022
Q2 | $2.18M | Sell |
39,164
-27,998
| -42% | -$1.66M | 0.02% | 306 |
|
|
2022
Q1 | $4.16M | Sell |
67,162
-9,118
| -12% | -$558K | 0.05% | 139 |
|
|
2021
Q4 | $4.2M | Buy |
+76,280
| New | +$3.98M | 0.05% | 160 |
|
|
2019
Q2 | – | Sell |
-87,116
| Closed | -$10.3M | – | 887 |
|
|
2019
Q1 | $10.3M | Buy |
87,116
+11,045
| +15% | +$1.11M | 0.07% | 118 |
|
|
2018
Q4 | $6.98M | Sell |
76,071
-14,777
| -16% | -$1.5M | 0.05% | 134 |
|
|
2018
Q3 | $10.2M | Buy |
90,848
+17,459
| +24% | +$1.84M | 0.07% | 121 |
|
|
2018
Q2 | $6.76M | Buy |
73,389
+5,234
| +8% | +$508K | 0.04% | 143 |
|
|
2018
Q1 | $6.8M | Buy |
68,155
+11,845
| +21% | +$1.28M | 0.05% | 124 |
|
|
2017
Q4 | $5.28M | Buy |
56,310
+6,265
| +13% | +$593K | 0.04% | 138 |
|
|
2017
Q3 | $5.09M | Buy |
50,045
+4,177
| +9% | +$365K | 0.04% | 143 |
|
|
2017
Q2 | $3.51M | Buy |
45,868
+6,200
| +16% | +$521K | 0.02% | 153 |
|
|
2017
Q1 | $3.42M | Sell |
39,668
-4,641
| -10% | -$334K | 0.02% | 155 |
|
|
2016
Q4 | $2.84M | Sell |
44,309
-14,473
| -25% | -$891K | 0.02% | 160 |
|
|
2016
Q3 | $3.8M | Sell |
58,782
-5,993
| -9% | -$338K | 0.03% | 152 |
|
|
2016
Q2 | $3.59M | Buy |
64,775
+20,901
| +48% | +$1.05M | 0.03% | 141 |
|
|
2016
Q1 | $1.84M | Sell |
43,874
-7,519
| -15% | -$349K | 0.02% | 155 |
|
|
2015
Q4 | $3.23M | Buy |
+51,393
| New | +$2.63M | 0.03% | 146 |
|
Other funds holding LKFT
ALPS Advisors's LKFT Position: Q3 2026 in Review
ALPS Advisors increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 35% in Q3 2026, buying an estimated $651K and bringing the position to 88,253 shares worth $2.62M. The position accounts for 0.01% of the portfolio, ranked #450.
ALPS Advisors first reported a position in LKFT in Q4 2015 and has held it in 34 quarters since. The position peaked at $10.3M in Q1 2019. 28 funds tracked by Wall St. Rank hold LKFT as of Q3 2026.
- ALPS Advisors held 88,253 shares of Lakefront Biotherapeutics American Depositary Shares worth $2.62M as of Q3 2026.
- ALPS Advisors bought 22,730 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2026, an estimated $651K.
- Lakefront Biotherapeutics American Depositary Shares made up 0.01% of ALPS Advisors's portfolio in Q3 2026, its #450 holding.
- ALPS Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2015 and has held it in 34 quarters since.
- ALPS Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $10.3M in Q1 2019.
- 28 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2026.
Based on ALPS Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.